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Abstract-A purification procedure for rat and mouse brain histamine N-methyltransferase (HMT. 
EC 2.1.1.8) is described which achieves the preparation of 87-fold purified rat brain and 166-fold 
purified mouse brain enzyme. The purified HMT (MW 29.000) is inhibited by a number of physiologi- 
cally and pharmacologically active amines. among them several methylated indoleamines. at concen- 
trations above 5 x M. At concentrations below 1 x lo-’ M. most of the methylated indoleamines 
stimulate HMT, provided histamine is maintained at, or close to, its optimal concentration as an 
HMT substrate, namely 1 x to -$  M. A study of the nature of the inhibitory process revealed a non-com- 
petitive inhibition of HMT by dopamine as against a competitive inhibition of the enzyme by most 
methylated indoleamines. Increasing the concentration of histamine beyond the optimal value, i.e. to 
inhibitory levels, resulted in less stimulation. The findings support the notion that MSO elicits the 
formation in selected brain cells of supranormal amounts of several methylated indoleamines which 
are able to stimulate HMT (and possibly other methyltransferases, see SALAS et al., 1977), thereby 
causing the depletion of the cerebral levels of S-adenosyl-L-methionine, reported previously (SCHATZ 
& SELLINGER, 1975b). 
THE PRINCIPAL catabolic pathway for histamine in 
rodent brain is by methylation to  1-methyl histamine2 
and by further oxidation of the latter t o  l-methylimi- 
dazoleacetic acid. As we have recently shown (SCHATZ 
& SELLINGER, 1975a), the activity catalyzing the meth- 
ylation of histamine, histamine N-methyltransferase 
(HMT, EC 2.1.1.8) becomes elevated in both mouse 
and rat brain following the administration of the con- 
vulsant agent L-methionine-dl-sulfoximine (MSO). 
Since this treatment also leads to  a marked depletion 
of cerebral S-adenosyl-L-methionine (SCHATZ & SELL- 
INGER, 1975b), we proposed (SCHATZ & SELLINGER, 
19750) that MSO elicits the accumulation within 
selected brain cells of methylated HMT-stimulating 
substances. To begin testing this notion, we decided 
to  examine first the effectiveness of several naturally 
occurring and biologically potent ( ROSENGARTEN & 
FRIEDHOFF, 1976; GILLIN et al., 19760) methylated in- 
doleamines as HMT modulators in uitro. To ensure 
a high specificity of interaction between the methy- 
lated indoleamines and the HMT protein, we purified 
HMT from mouse and rat brain and we also tested 
the effect of several of the amines found active with 
’ Supported by a United States Public Health Service 
grant. NINCDS 06294. 
Abbreuiations used: HMT. histamine N-methyltransfer- 
ase; MSO. L-methionine-dl-sulfoximine; PNMT. phenyl- 
ethanolamine N-methyltransferase; DTT. dithiothreitol; 
COMT. catechol 0-methyltransferase. 
By the ‘histamine nomenclature‘ (see BARTH e f  al.. 
1973). In the ‘histidine nomenclature’ (see SCHAYER &
REILLY. 1975) this is 3-methylhistamine. 
H M T  on  another methyltransferase, phenylethanol- 
amine N-methyltransferase (PNMT, EC 2.1.1.28). In 
addition, we purified HMT from brains of MSO- 
treated animals and compared its interaction with 
N,N-dimethyltryptamine to  that of the control 
enzyme. A preliminary account of some of the find- 
ings has appeared (SELLINGER el al.. 1976). 
EXPERIMENTAL PROCEDURES 
Animals. Adult, male Sprague-Dawley rats (200-250 g) 
and male Swiss-Webster mice (20-25 g) (Spartan Research 
Animals, Haslett, MI) were killed by decapitation and the 
brains (minus the cerebellum) rapidly excised and weighed. 
Usually 1S21 g of rat and 9-14g of mouse brain were 
worked up. 
Chemicals. The following substances were purchased 
from Sigma Co. (St. Louis. MO): dithiothreitol (DTT), 
ammonium sulfate (enzyme grade). sucrose (enzyme grade), 
DL-norepinephrine HCI. L-epinephrine, tryptamine HCI. 
imidazole, 3-hydroxytyramine HCI. 2-methylimidazole. 
N,N-dimethyltryptamine, 5-hydroxytryptamine. 5-hydroxy- 
DL-tryptophan, 5-hydroxyindoleacetic acid, 3-methoxytyra- 
mine, ~-3-methoxytyrosine, L-I-methylhistidine. N,N- 
dimethyl-5-methoxytryptamine HCI. 5methoxytryptamine 
HCI, L-tryptophan, a-methyl-DL-histidinediHCI, 5-meth- 
oxy-DL-tryptophan and L-3-methylhistidine. Regis Chemi- 
cal Co., Morton Grove, IL supplied N-methyl-3-hydroxy- 
tyramine HCI, N-methyl-5-hydroxytryptamine hydrogen 
oxalate, m-octopamine HCI. 4-methoxy-3-hydroxy- 
phenethylamine HCI. 4-methoxyphenethylamine HCI, 
3,4dimethoxyphenethylamine HCI. synephrine. melatonin. 
~~-3-m-dimethyl-tyrosine methyl ester HCI. N-methyltryp- 
tamine and N-acetyl dopamine. Tyramine HCI. Ldihyd- 
roxyphenylalanine and phenylethanolamine were from 
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ICN. Cleveland, OH. S-Adenosyl-r-methionine (hydrogen 
sulfate) was from Boehringer Mannheim Biochemicals. In- 
dianapolis, IN;  imidazoleacetic acid HCI. a-methyl-DL-tyr- 
osine and I-methyl-4-imidazoleacetic acid were from Cal- 
Biochem. Ldolla. CA; N.N-dimet hyl-5-hydroxytryptamine 
was from Aldrich Biochemicals. Milwaukee, WI and 
phenylethanolamine N-methyltransferase (rabbit adrenal 
medulla) from Miles Laboratories, Elkhart. IN. DEAE-cel- 
lulose was a product of Whatman. Inc.. Clifton. NJ: 
Sephadex G-100 and the protein molecular weight calibra- 
tion kit were from Pharmacia. Piscataway. NJ. S-Adeno- 
syl-~-[Me-~~C]methionine (sp c.act. 4&65 mCi/mmol) was 
from New England Nuclear, Boston. MA or from Research 
Products International. Elk Grove Village. IL. PCS (phase 
combining system) used in liquid scintillation counting was 
from Amersham/Searle. Arlington Heights, 1L. All other 
chemicals were of the best reagent grade available. 
Chromatography and relared procedures. Chromato- 
graphic procedures were carried out on columns and with 
accessories supplied by Pharmacia. Piscataway. NJ. Dialy- 
sis and desalting were by means of the hollow fiber device 
(BioRad 50) (BioRad Laboratories, Richmond, CA) and 
reductions of volume by means of stirred cells provided 
with XM-50 filters (Amicon Corp.. Lexington. MA). 
Assay of histamine N-merhylrransjerase. H M T  was 
assayed according to SNYDER & AXELROD (1965) under 
conditions described in a previous paper (SCHATZ & SELL- 
INGER. 1975a). Authentic I-[Me-14C]methylhistamine was 
prepared as previously described (SCHATZ & SELLINGER, 
1975a) and I x 10-5M-histamine was used as substrate. 
higher concentrations proving inhibitory (SCHATZ & SELL- 
INGER. 1975a). The concentration of S-adenosyl-L-meth- 
ionine (including S-adenosyl-~-[Me-~~C]methionine) was 
maintained at 3.2 x I O - ' M  throughout the study. The 
blank tubes contained no histamine. All test-substances 
were initially tested for interference in the H M T  assay 
(TAYLOR & SNYDER, 1972) by adding them to the incuba- 
tion mixtures either before or at the end of the incubation 
and then proceeding with the extraction steps. None of 
the substances tested was found to interfere with the quan- 
titative extraction of 1-[Me-'4C]methylhistamine, the only 
detectahle reaction product (Schatz. Ashcraft & Sellinger. 
unpublished observations) of cerebral H M T  and none was 
found to affect the pH of the incubation mixture. 
PNMT was assayed according to  DEGUCHI & BARCHAS 
(1971) under the precise conditions more recently described 
by LEW er a/. (1976). with phenylethanolamine as substrate. 
The above tests for interference were repeated and found 
satisfactory. 
Protein was determined by the method of LOWRY et 
a/. (1951). 
The adminisrrarion of MSO. Injections were intraperi- 
toneal. at a dose of 0.97 mmol/kg. The animals were killed 
3 h after the single dose. 
The pur$carion of histarnine N-merhyltransferase from 
mouse and rat brain. The weighed brains were homogenized 
in 10 vol of 0.25 M-sucrose and the homogenate centrifuged 
at 80,OOOg for 30min in Beckman rotor SW-27. Solid 
ammonium sulfate was added to the resulting supernatant 
t o  achieve 45% saturation (4°C) and the resulting precipi- 
tate was centrifuged off. The supernatant was brought to  
80% saturation and the precipitate collected and suspended 
by gentle stirring in a volume of 1OmM-Na phosphate 
buffer (pH 7.4) containing 1 mM-DTT and approximately 
double the original brain weight. This solution was dia- 
lyzed for about 20h  against two changes of 21 each of 
1 mM-Na phosphate buffer. pH 7.4. containing 
0.1 mM-DTT at 4°C. Five to  ten millilitres of the dialyzed 
solution were introduced from the bottom onto a Pharma- 
cia K 26/70 column previously packed with DEAE-cellu- 
lose and equilibrated with 10 mM-Na phosphate buffer, pH 
7.4. containing 1 mM-DTT. After 125 ml of the equilibrat- 
ing buffer, elution was begun by means of a convex gra- 
dient formed by mixing 125 ml of the equilibrating buffer 
with 175 ml of the same buffer containing 2 M-NaC1. The 
flow rate was about 1 ml/min. The effluent was con- 
tinuously monitored at 280 nm. the fractions containing 
enzyme activity pooled, dialyzed against 2 1 of 1 mM-Na 
phosphate buffer. pH 7.4. containing 0.1 mM-DTT and 
desalted. The volume was reduced to about 5 m l  which 
were introduced from the bottom onto a Pharmacia 
K 16/70 column packed with Sephadex G-100 and equili- 
brated with 25 mM-Na phosphate buffer. pH 7.4, contain- 
ing 0.5mM-DTT. Elution was with the same buffer, also 
containing 0.3 M-NaCI. The fractions containing enzyme 
activity were pooled and stored on ice. Freezing of solu- 
tions containing H M T  was avoided. as all activity was 
promptly lost. 
Enzyme uelocity and kineric constanrs. The velocity 
and/or activity of H M T  is expressed as d.p.m. I-[Me-14C]- 
methylhistamine formed/30 min. With the knowledge that 
8850 d.p.m. represents one nmol of 1-[Me-'4C]methylhis- 
tamine. the interconversion between d.p.m. and nmol is 
readily attained; for simplicity. we chose to express the 
velocity of H M T  in radioactivity units. except when com- 
paring H M T  from control and MSO-treated animals. In 
that case. H M T  velocities are expressed in 
d.p.m./30min/mg of protein. The apparent K, and K i  
values are in mol/l (M).  
RESULTS 
The purification of rat and muse brain HMT 
The 4-step purification procedure (Tables 1 and  2) 
yielded 87- a n d  166-fold purified enzyme from rat  a n d  
mouse brain. T h e  recoveries were between 12 and 
16% of the  original tissue homogenate  activity. 
Figures  1 a n d  2 s h o w  the  elution profiles of HMT 
o n  DEAE-cellulose a n d  o n  Sephadex G-100. M o u s e  
HMT occasionally exhibited t w o  activity peaks or a 
peak and a shoulder  on DEAE-cellulose (see Fig. 1 b), 
bu t  after Sephadex, such  heterogeneity (AXELROD & 
VESELL, 1970; SURIYACHAN & THITHAPANDHA, 1972) 
was no longer detectable. Gel-filtration on Sephadex 
G-100 of the  purified enzyme against molecular 
weight cal ibrat ion s tandards  yielded a molecular 
weight of 29.000 f 1500 (range f rom 2 rat  a n d  2 
mouse  experiments). The purified enzyme remained 
active for up t o  3 weeks a t  4°C. 
Survey of eflectioe amines 
Initially a series of amines were tested at several 
concentrat ions (4 x lo-' M-2.5 x M) and with 
both  ra t  and mouse HMT (purified through t h e  
Sephadex step). The concentrat ion of histamine was 
kept  a t  1 x lo-' M. previously established as t h e  opti- 
mal  concentrat ion (SCHATZ & SELLINGER. 1975a) a 
fact which was confirmed in preliminary experiments 
using t h e  purified enzyme. S t rong  inhibition of HMT 
Methylated indoleamines and brain HMT 439 
TABLE I. PURIFICATION F RAT BRAIN HISTAMINE N-METHYLTRANSFERASE 
Protein Enzyme activity 
Volume Total Specific Tctal Purification Yield 
Fraction (ml) (mg/ml) (mg) activity activity (x-fold) (zl) 
Homogenate 1 I8 18.1 2.149 780 1.68 x loh 100 
80.000 u 





concentration) 4.4 1.23 5.45 45.200 2.47 x lo5 57.6 14.7 
Sephadex G-100 32.3 0.088 2.85 68.200 1.94 x lo5 87.3 11.6 
dialysis) 10.0 1.23 123 4.530 5.57 x 105 5.8 33.3 
TABLE 2. PURIFICATION OF MOUSE BRAIN HISTAMINE N-METHYLTRANSFERASE 
Fraction 
Protein Enzyme activity 
Volume Total Specific Total Purification Yield 
(ml) (mg/ml) (mg) activity activity (x-fold) (X) 
100 Homogenate 73 13.3 967 1,580 1.53 x lo6 - 
80,000 8 
supernatant 70 3.54 248 2.850 7.04 x 105 1.8 46.0 
Ammonium sulfate 
(4S80%. after 
dialysis) 10.3 2.23 22.3 39.300 8.75 x 105 25.0 57.0 
DEAE-cellulose 
(after eluate 
Sephadex G-100 26.3 0.035 0.93 261,800 2.47 x lo5 166.0 16.2 
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FIG. 1. Chromatography of cerebral HMT on DEAE cellu- 
lose. (a) After exhaustive dialysis of the 45-80'4 (NH4)2S04 
precipitate suspended in 10 mM-Na-phosphate buffer, pH 
7.4, also containing 1 mM-DTT. the enzyme (10 ml, 12.3 mg 
of protein) was loaded onto a DEAE-cellulose column (see 
text) and eluted by means of a gradient increasing in NaCl 
(see text for details). The left ordinate. M. denotes 
1-[Me-'4C]methylhistamine formed/30 min: - - - - - - -  : 
absorbance at 2 8 0 n ~  tracing the elution of protein. (b) 
As in (a). except that a mouse brain HMT preparation 
(10.3 ml, 23 mg of protein) was chromatographed. Note 
second peak of HMT activity, 0---0 (tubes 42-47) and 
also the left ordinate scale (HMT activity) is 10 times 
higher than in (a). 
(0 )  - - 0.5 
- 0.4 
Y - 0.3 
" 5 0  I .  I 
x 40 
- 0.1 a 
a 20 
'. -___- -  0 
Tube No. 
FIG. 2. Gel-filtration of cerebral HMT on Sephadex G-100. 
(a) The pooled eluate of the DEAE cellulose column (Fig. 
1) (4.4m1, 5.4mg of protein) was applied to a column of 
Sephadex G-100 (see text. for details) and the rat brain 
HMT was eluted as described in the text. The left 
ordinate denotes I-[Me-'4C]Methylhi~tamine formed 
(d.p.m.)/30 min (w); -------: absorbance at 280 nm, 
tracing the elution of protein. (b) As in (a) except that 
5.6 m (1.96 mg) of mouse brain protein were applied to 
the column. 
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was achieved by dopamine, tyramine. octopamine. 
3-methoxydopamine and 4-methoxyphenethylamine. 
over the 4 x lo-' M-2.5 x M range of concen- 
trations. Weak inhibition was seen with 4-methoxydo- 
pamine. No inhibition was noted with 2.5 x 1 0 - 6 ~  
synephrine. N-methyldopamine, 3.4-dimethoxyphenyl- 
ethylamine, L-3-methoxy-tyrosine. 5-methoxy-DL- 
tryptophan, L-I-methylhistidine, 1-methyl-Cimida- 
zoleacetic acid, imidazoleacetic acid, a-methyl-DL- 
tyrosine. L-tryptophan. L-dihydroxyphenylalanine. 
a-methyl-DL-histidine, L-3-methylhistidine, 5-hydroxy- 
tryptophan, 5-hydroxyindoleacetic acid, imidazole, 
norepinephrine and 2-methylimidazole. Among the 
tryptamines. inhibition was noted with tryptamine, 
5-hydroxytryptarnine (MERRIL et a!., 1966), 5-meth- 
oxytryptamine. N,N-dimethyl-5-hydroxytryptamine, 
N.N-dimethyl-5-methoxytryptamine, while N-ace- 
tyl-5-methoxytryptamine had no effect. N-Methyl-5- 
hydroxytryptamine and N.N-dimethyltryptamine 
consistently stimulated at 4 x lo-' M and inhibited 
at 2.5 f 1 0 - 6 ~  in a manner analogous to the H I  
and H2 histamine receptor blockers, mepyramine and 
burimamide (TAYLOR. 1973). When some of the above 
listed amines were retested at 2.5 x lo-' M. alone and 
in pairs, N.N-dimethyltryptamine was again found to 
stimulate HMT. The results shown in Table 3 also 
indicate that HMT activity was intermediate when 
determined in the presence of N,N-dimethyltrypt- 
amine + tryptamine and maximal and minimal. re- 
spectively when determined in the presence of either 
amine alone. While dopamine exerted little influence 
on the stimulation of HMT by N,N-dimethyltrypt- 
amine. tryptamine and 5-methoxytryptamine com- 
TABLE 3. THE EFFECT OF A COMBINATIOK OF INHIBITORY AND 
N-METHYLTRANSFERASE 






Dopamine + tryptamine 69 
5-Methoxytryptamine 108 
5-Methoxytryptamine + 95 
dopamine 
5-Methoxytryptarnine + 12 
tryptamine 
N.N-Dirnet hyltryptarnine 159 
N.N-Dimethyltryptamine + 142 
dopamine 
N,N-Dimethyltryptamine + 63 
tryptarnine 
5-methoxytryptamine 
N.N-Dirnethyltryptamine + 95 
* 2.5 x lo-' M ;  histamine: 1 x lo-' M .  
The incubations were for 30min in the presence of 
Sephadex-purified mouse brain HMT. Each amine. 
whether incubated alone or as a member of a pair, was 
at the concentration indicated. 
pletely abolished it even though the latter amine had 
virtually no effect on HMT when tested alone. 
Eflecr of modulator and histamine concentrations 
In an effort to extend the above observations HMT 
was incubated in the presence of a wide range 
M-lo-' M) of concentrations of S-methoxytrypt- 
amine. NJdimethyltryptamine, N,N-dimethyl-S- 
methoxytryptamine, N-methyl-5-hydroxytryptamine 





140 ,tryptamine .tryptamine 




-8 [Histomine] = I x 10-5M 
[Modulator], M 
FIG. 3. Efiect of modulator concentration on the activity of rat brain HMT. Rat brain HMT. purified 
through the Sephadex G-100 step (Table 1) was incubated at 1 x M ( - - - - - - - )  
histamine (except for 5-methoxytryptamine which was not incubated at 1.25 x M-histamine) and 
in the presence of the indicated concentrations of 6 methylated indoleamines (modulator) and the 
amount of l-[Me-'4C]methylhistamine formed in 30min was determined. The values are plotted as 
'6 of those obtained in the absence of modulator (control HMT = 100%). 
M and 1.25 x 
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and NJ-dimethyl-5-hydroxytryptamine and its ac- 
tivity determined at 1 x lo-' M and 1.25 x 1 0 - 6 ~  
Stimulation was limited to a narrow range of hista- 
mine concentrations ( lO-'~-2.5 x 1 0 - 6 ~ ) .  
histamine (except for 5-methoxytryptamine). Figure 3 
illustrates the typical pattern of stimulation of HMT 
by a range of amine concentrations (5 x M and 
1 x M) together with its dependence on the pre- 
vailing concentration of histamine. Thus, none of the 
methylated indoleamines stimulated HMT at the 
lower histamine concentration. Conversely, HMT was 
uniformly inhibited at amine concentrations above 
5 x M and, as indicated in Fig. 3. this inhibition 
was significantly more severe at the lower of the two 
histamine concentrations. 
The substrate dependence of the stimulation of 
HMT was further examined by determining its ac- 
tivity over a 10-5-8 x ~ O - ' M  range of histamine 
concentrations and in the presence of either an inhibi- 
tory (1 or 4 x 1 0 - 6 ~ )  or a presumed stirnulatory 
(2.5 x lo-' M, 7 x M )  modulator 
concentration. The Lineweaver-Burk ( l / u  vs l/s) plots 
(Fig. 4) show inhibition with the compounds shown 
effective in Fig. 3 (panels d, e and f )  and, unexpec- 
tedly, with 5-methoxytryptamine as well (panel c). 
M or 4 x 
The nature of the modulator-HMT interaction 
The overall effects of selected methylated indole- 
amines on HMT activity were further tested by exa- 
mining them at more than one concentration of hista- 
mine. The results of these experiments yielded the 
Dixon plots ( [ I ]  vs. l/o) shown in Fig. 5 (a-c: mouse; 
d-f: rat) and permitted the calculation of selected K ,  
values (Table 4). The deviations from linearity noted 
in the presence of N,N-dimethyltryptamine, 5-meth- 
oxytryptamine and NJ-dimethyl-5-methoxytrypta- 
mine consisted of concave-upwards curvatures in the 
[I] vs l / u  lines at close to or saturating concen- 
trations of histamine, confirming their HMT-stimula- 
tory action under these conditions (panels b, e and 
9. A comparison of the Ki values (Table 4) with the 
apparent K ,  value for histamine revealed a non-com- 
petitive inhibition by dopamine (Fig. 5,  panels a and 
d) vs a competitive inhibition by the methylated in- 
doleamines, particularly those containing two or three 
methyl groups per molecule. To analyze their HMT- 
( 0 )  
N- Methyltryptamine (b) 
40 N.N -Dimethyl-5-OCH3- (C)  
44 5-OCH3-Tryptomirm 
28 
12 12 0 
0 
4 4 
0.2 0.6 ID 1.4 0.2 0.6 1.0 1.4 0.2 0.6 1.0 1.4 
I/  [Histamine]( 10-6M) I/ [Histamine] (IO-6M) I/ [Histamine] (IO-'M) 












0.2 0.6 1.0 1.4 0.2 0.6 1.0 1.4 0.2 0.6 1.0 1.4 
I /  [Histomine](IO-*M) I /  [Histamine] (IO-6M) I/[Histomine] (IO-'M) 
FIG. 4. The modulation of HMT by methylated indoleamines: Lineweaver-Burk plots. All panels: 
rat brain HMT, except panel f, M: mouse brain HMT. 
indoleamine. Note stimulation of HMT in all panels. u = total l-[Me-14C]methylhistamine 
(d.p.m.)/30 min x except for panel f (M) where u = total l-[Me-14C]methylhistamine 
(d.p.m.)/30 min x LO-' M .  Concentrations by the arrows are those of the methylated indoleamine. C: 
control. Note that in this experiment 7 x lo-' M-N.Ndimethyltryptamine (panel 0 stimulated rat brain 
HMT (M) only at 1 x M-histamine, while 2.5 x lo-' M-N,N-dimethyltryptamine stimulated 
mouse HMT (M) at 3 histamine Concentrations. 
indicates presence of 4 or 7 x 
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[Histamine] = 
I x o-=u 
-2-1 0 I 2  3 4 5 6 






J 01'1"''" 0- 
I 1 2 3 4 5 6 7 8 9 1 0  1 2 3 4 5 6 7 8  
[N,N-Dirnethyltryptamine] x 10% [5-OCH3 Tryptomind x IO'OM 
- 2 - 1 0 1  2 3 4 5 6 7  1 2 3 4 5 6 7 0 9 0  I 2  3 4 5 6 7 8  
[N,N - Dimet hyl -5 - O W 3  - 
[Doparnine] x 10% [N,N-Dirnethyltryptamine] x lO-'M [5-OCH, Tryptomine] x 10%- 
trypiamine] x 10''~ - 
FIG. 5. The modulation of HMT by methylated indoleamines: Dixon plots. Panels a-c: mouse brain 
HMT; panels d-f: rat brain HMT. In panels a. c (right ordinate), d. e and f. u = total 1-[Me-l4C] 
methylhistamine(d.p.m.)/30 min x lo', whilein panels b and c (left ordinate) u = total 1-[Me-l4C]methyl- 
histamine (d.p.m.)/30min x lo6. Dotted lines are drawn as if no activation occurred (panels b, e and 
f )  or, in the case of dopamine (panels a and d) they converge on the negative abscissa, indicative 
of non-competitive inhibition. Note that mouse (a-c) and rat (d-r) HMT were tested at different modu- 
lator concentrations. 
stimulatory effectiveness, the methylated indoleamines 
(10-7-10-8~) were incubated with H M T  over a 
10-fold range of histamine concentrations which in- 
cluded both half and 5-times optimal values. Figure 
6 illustrates maximal H M T  stimulation at  
1 x M-histamine, with residual stimulation at  
higher concentrations particularly by the di- and tri- 
methylated compounds. The Lineweaver-Burk repre- 
sentation (Fig. 6b) indicates that. with the exception 
of N-methyltryptamine. the methylated indoleamines 
stimulated H M T  'non-competitively.' 
The action 01 methylated indoleamines on adrenal 
phenylethanolamine-N-methyltransferme 
Several methylated indoleamines were also tested 
with rabbit adrenal PNMT. In these experiments the 
concentration of phenylethanolamine was varied over 
TABLE 4. K i  VALUES FOR INHIBITION OF RAT AND/OR MOUSE BRAIN HISTAMINE N-METHYLTRANSFERASE BY DOPAMINE AND 
3 METHYLATED INDOLEAMINES 
Modulator Ki Species Type of inhibition 
- None 5.0 x rat, mouse 
Dopamine 4.5 X 1 o - ' M  rat non-competit ive 
Dopamine 4.0 x 1 0 - 7 ~  mouse non-competitive 
N,N-Dimethyltryptamine 7.0 X lo-' M i  rat competitive 
N. N-Dimethyl-5-rnethoxytrypt amine 1.6 X I o - ' M t  rat competitive 
5-Methoxytryptamine 1.2 X 10-6M mouse competitive 
K, (Mean of 13 determinations). 
t Determined by extrapolation of dashed lines, panels (e) and (I), Fig. 5 and on the assumption of no HMT stimulation. 
The K i  values were obtained graphically from the Dixon plots, shown in Fig. 5. Sephadex-purified HMT was used 
for all determinations. 
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1.0 2.0 30 4.0 5.0 
[Histamine] x 10% 
FIG. 6. The modulation of rat brain HMT by methylated 
indoleamines in the presence of inhibitory concentrations 
of histamine. (a) Michaelis-Menten plot. u = total 
1-[Me-'*C]methylhistamine (d.p.m.)/30 min x lo3. 0: con- 
trol; V: 1 x M-N-methyltryptamine; A:  1 x M- 
N-methyl-5-hydroxytryptamine; U: 7 x lo-' M - N , N -  
dimethyltryptamine; 0: 7 x lo-' M-N.N-dimethyl-5-meth- 
oxytryptamine and B: 7 x lo-' ~-N.Ndimethyl-S-hyd- 
roxytryptamine. (b) Lineweaver-Burk plot of (a). u = total 
l-[Me-14C]methylhistamine (d.p.m.)/30 min x lo-' M. 
a 20-fold range which included the apparent saturat- 
ing concentration (a. 5 x lo-'  M) and the reported 
K, concentration (0.4 x 10-'M; LEW et a/., 1976). 
Table 5 illustrates the two main features of the 
methyl-indoleamine-PNMT interaction: (a) a marked 
inhibition by N-methyltryptamine which appeared to 
decrease as the concentration of the substrate was 
raised; and (b) a tendency toward stimulation of the 
enzyme by N-methyl-5-hydroxytryptamine and N,N- 
dimethyl-5-hydroxytryptamine; 5-methoxytryptamine 
and N,N-dimethyltryptamine were without effect 
(data not shown). 
Histamine N-rnethyltransferase from MSO-treated ani- 
mals (MSO-HMT) 
Several experiments were carried out in which mice 
or rats were pretreated for 3 h with a convulsant dose 
of MSO (0.97 mmol/kg) and HMT was then purified 
through the Sephadex step to be compared to  the 
control enzyme purified in parallel. Control and 
MSO-HMT were incubated over a 10-fold range of 
histamine concentrations in the presence of 
7 x lo-' M-N,N-dimethyltryptamine (a stirnulatory 
concentration, see Figs. 3 and 5 )  as well as over a 
100-fold range of N,N-dimethyltryptamine concen- 
trations at 1 x 1O-'M and 1.25 x 10-6~-histamine. 
These studies revealed that MSO-HMT was also 
stimulated by N,Ndimethyltryptamine at close to 
saturating concentrations of histamine and that the 
control and the MSO-HMT exhibited closely similar 
K i  values for N,N-dimethyltryptamine (ca. 
7 x lo-' M )  when determined at 1 x lo-' M-hista- 
mine. 
TABLE 5. THE ACTION OF METHYLATED INWLEAMINES ON ADRENAL PHENYLETHANOLAMINE N-METHYLTRANSFERASE: DEPEN- 
DENCE ON SUBSTRATE CONCENTRATION 
Methylated [Phenylethanolamine] x lo-' M 





4 x ~ o - ~ M  
1 X 1 0 - 6 M  
868 1086 1523 1501 1484 1387 
100 100 100 100 100 100 
43 50.5 47 60 75.5 84.5 
25 32.5 38.5 60 59 70.5 
Expt. 2 
None, Units* 1394 1859 2057 1932 2441 2000 
None, % 
N-Methyl-5-hydroxytryptamine 
4 X 1o-*M 
1 x 1 0 - 7 ~  
I x 1 0 - 7 ~  
N,N-Dimethyl-5-hydroxytryptamine 
4 X 10-'M 
100 100 100 100 100 100 
88 82 97 114 87 100 
89 83 111 122 99 100 
93 96 117 122 92 103 
68 66.5 102 I02 98 100 
* d.p.m. of ['*C]methylated product/h. 
The contents of a vial of rabbit adrenal PNMT (14mg) as supplied, were dissolved in one ml of distilled water 
and 0.05ml used per assay. Incubations were at 37°C for 30min. The remainder of the enzymic determination was 
as described by DEGUCHI & BARCHAS (1971). 
444 0. Z. SELLINGER. R. A. SCHATZ and W. G .  OHLSSON 
DISCUSSION 
The present study is the first to report an extensive 
purification of cerebral HMT. On the average, the 
procedure outlined in Tables 1 and 2 yielded rat and 
mouse brain HMT 2.5 and 4.6 times purer than the 
previously available 36-fold purified guinea-pig brain 
HMT (BROWN et al.. 1959). Efforts to purify HMT 
from non-neural tissues have yielded a 260-fold puri- 
fied pig-liver preparation (GUSTAFSSON & FORSCHELL, 
1963) and a 120-fold purified. but highly unstable, 
HMT preparation from the mucosa of the pig antrum 
(LORENZ et a/.. 1972). It is of interest to note that 
TAYLOR & SNYDER (1972) used merely 6-fold purified 
mouse brain HMT to carry out a comprehensive 
study of its inhibition and potentiation by antihista- 
mines. 
The molecular weight of 29,000 for the rat and 
mouse brain HMT compares with the recently 
reported molecular weights of 25,000 and 26,000 re- 
spectively, for cerebral catechol 0-methyltransferase 
(COMT. EC 2.1.1.6) (WHITE & Wu, 1975) and PNMT 
(DIAZ BORGES & URBINA, 1976). However, in view 
of: (a) the differential regional and cellular localiza- 
tions of HMT, PNMT and COMT in brains of differ- 
ent species (SAAVEDRA et a!., 1974; GARBARG et a/.. 
1975; MEZEI, 1975; SAAVEDRA et a/., 19760; VOGEL 
et al.. 1976; LEW et a/., 1977); (b) their different deve- 
lopmental patterns (MARTRES et al.. 1975; MEZEI. 
1975; KOUVELAS ut a/., 1976); (c) their different pat- 
terns of molecular heterogeneity (AXELROD & VESELL, 
1970; SURIYACHAN & THITHAPANDHA. 1972; WHITE 
& Wu. 1975); and (d) their different sensitivities 
toward different modulating processes (ORR & QUAY, 
1975; SCHATI. & SELLINGER. 1975a; SAAVEDRA ef a/., 
197663, any inference regarding molecular similarities 
among the three methyltransferases and, hence, by 
extension, of common mechanisms regulating their 
activities in oioo is at this time premature. 
Although cerebral HMT is affected in oitro by a 
wide variety of pharmacologic agents (TAYLOR & 
SNYDER, 1972; BARTH et al., 1973; SCHAYER & REILLY. 
1975; DUCH et al.. 1976) some of which act in an 
apparent stimulatory manner (TAYLOR & SNYDER, 
1972; BARTH et a/.. 1973; TAYLOR, 1973). its modula- 
tion by methylated indoleamines has not been de- 
scribed. HARTLEY & SMITH (1973) recently reported 
a significant stimulation of the bovine pineal hydroxy- 
indole 0-methyltransferase by N,N-dimethyltrypt- 
amine and N,N-dimethyl-5-methoxytryptamine 
(tested at 1.2 x 1 0 - 4 ~ ) .  The modulation of cerebral 
HMT by the methylated indoleamines consisted of 
inhibition and stimulation in a manner strictly depen- 
dent on the prevailing concentration of histamine. 
Figures 3 and 4 summarize the effects of 6 methylated 
indoleamines. As may be seen (Fig. 4). HMT inhibi- 
tion by 1-4 x 1 0 - b ~  modulator was competitive 
with respect to histamine. Stimulation of HMT was 
noted at or close to I x M-histamine and was 
achieved at 4-7 x 1 0 - * ~  (rat) or 2.5 x IO-’w 
(mouse) modulator. 
Our findings thus reveal that methylated indole- 
amines “can go from inhibition to stimulation (or the 
reverse) by varying the substrate” (REINER, 1959). A 
similar situation was recently described by LOMBAR- 
DIN] et 01. (1973) with ATP: L-methionine S-adenosyl- 
transferase (EC 2.5.1.6) of rat liver. an enzyme we 
recently compared in rat brain cerebral cortex and 
cerebellum (DIEZ ALTARES & SELLINGER, 1976). These 
workers noted activation of the enzyme by ‘low’ 
(0.7-2 x 1 0 - 3 ~ )  and inhibition by ‘high’ 
(3.5-16.5 x M) concentrations of several modu- 
lators, both effects being strongly dependent on the 
concentration of one of the substrates, L-methionine. 
However, unlike in the present study, high concen- 
trations of methionine led to inhibition rather than 
stimulation of the enzyme. Thus the present and 
seemingly unique situation in which low 
(10-7-10-8 M) modulator concentrations stimulate 
HMT maximally at, or close to. saturating substrate 
concentrations (Fig. 6) appears to rule out mechan- 
isms based on ‘cooperative effects between success- 
ively bound molecules’ (LOMBARDINI et al., 1973). Pre- 
sently, we prefer a mechanism of stimulation wherein 
the modulator affects a regulatory site of HMT and 
in so doing improves the interaction and/or the fit 
of the saturating histamine with the catalytic site of 
the enzyme. It is of interest that some of the sub- 
stances found effective in the present study have pre- 
viously been implicated as neuro-or schizotoxins 
(ROSENGARTEN & FRIEDHOFF, 1976; GILLIN et al.. 
1976a,b). The epileptogenic action of MSO could 
therefore derive from the drug’s ability to bring about 
a certain degree of ‘hypermethylat ion’. Evidence in 
support of this possibility continues to accrue 
(SCHATZ et al.. 1976, 1977; SCHATZ & SELLINGER, 
1977; SALAS et al., 1977). 
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